Role of the endocrine system in the pathogenesis of non-alcoholic fatty liver disease;Az endokrin rendszer szerepe a nem alkoholos zsírmáj kialakulásában

Orvosi Hetilap

Volumn 150, Issue 48, 2009, Pages 2173-2181

  Hagymási, Krisztina ^a,b   Reismann, Péter ^c   Rácz, Károly ^c   Tulassay, Zsolt ^c  

^a Semmelweis Egyetem   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c NONE

Author keywords

Adipokines; Endocrine system; Growth hormone; Hypothyroidism; Metabolic syndrome; Non alcoholic fatty liver; Polycystic ovary syndrome

Indexed keywords

ACYLATION STIMULATING PROTEIN; ADIPONECTIN; AMINOTRANSFERASE; GLUCAGON LIKE PEPTIDE 1; INSULIN; LEPTIN;

ADRENAL INSUFFICIENCY; CARDIOVASCULAR DISEASE; CUSHING DISEASE; ENDOCRINE SYSTEM; ENZYME ACTIVITY; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPERANDROGENISM; HYPERLIPIDEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHYROIDISM; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PHENOTYPE; POSTMENOPAUSE; PREMENOPAUSE; REVIEW; RISK ASSESSMENT; SLEEP APNEA SYNDROME; STEATOSIS;

EID: 70450225534     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2009.28749     Document Type: Review

References (50)

1. Kim, C. H., Younossi, Z. M.: Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome. Cleve Clin. J. Med., 2008, 75, 721-728.
2. Neuschwander-Tetri, B. A.: Nonalcoholic steatohepatitis and the metabolic syndrome. Am. J. Med. Sci., 2005, 330, 326-335.
3. Feher J., Nemeth E., Lengyel G.: A nem alkoholos steatohepatitis (NASH) a metabolikus szindroma resze? Orv. Hetil., 2004, 145, 1499-1506.
4. Abel T., Feher J.: A nem alkoholos zsirmaj es a sziv-er rendszeri kockazat. Orv. Hetil., 2008, 149, 1299-1305.
5. Harper, M. E., Seifert, E.: Thyroid hormone effects on mitochondrial energetics. Thyroid, 2008, 18, 145-156.
6. Berkenstam, A., Farnegardh, M., Gustafsson, J-A.: Convergence of lipid homeostasis through liver X and thyroid hormone receptor. Mechanism Aging Dev., 2004, 125, 707-717.
7. Malik, R., Hodgson, H.: The relationship between the thyroid gland and the liver. QJM, 2002, 95, 559-569.
8. Duntas, L. H.: Thyroid disease and lipids. Thyroid, 2002, 12, 287-293.
9. Daher, R., Yazbeck, T., Jaoude, J. B. és mtsa: Consequences of dysthyroidism on the digestive tract and Viscera. W. J. Gastroenterol., 2009, 15, 2834-2838.
10. Lonardo, A., Carani, C., Carulli, N. és mtsa: 'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver pathogenesis. J. Hepatol., 2006, 44, 1196-1207.
11. Loria, P., Carulli, L., Bertolotti, M. és mtsa: Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat. Rev. Gastroenterol. Hepatol., 2009, 6, 236-247.
12. Jeong-Seon, J., Hiun-Suk, C., Young-Seok, C. es mtsai: Myxedema ascites: Case report and literature review. J. Korean. Med. Sci., 2006, 21, 761-764.
13. Lichanska, A. M., Waters, M. J.: New insights into growth hormone receptor function and clinical implications. Hormon Res., 2008, 69, 138-145.
14. Waters, M. J., Hoang, H. N., Fairlie, D. P. es mtsai: New insights into growth hormone acton. J. Mol. Endocrinol., 2006, 36, 1-7.
15. Pennisi, P. A., Kopchick, J. J., Thorgeirsson, S. es mtsai: Role of growth hormone (GH) in liver regeneration. Endocrinology, 2004, 145, 4748-4755.
16. Ichikawa, T., Hamasaki, K., Ishikawa, H. es mtsai: Non-alcoholic steatohepatitis and hepatic steatosis in patients with adult onset growth hormone defi ciency. Gut, 2003, 52, 914.
17. Takahashi, Y., Iida, K., Takahashi, K. es mtsai: Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone defi ciency. Gastroenterology, 2007, 132, 938-943.
18. Itoh, E., Hizuka, N., Fukuda, I. és mtsa: Metabolic disorders in adult growth hormone defi ciency: A study of 110 patients at a single institute in Japan. Endocr. J., 2006, 53, 539-545.
19. Salerno, M., Di Maio, S., Ferri, P. es mtsai: Liver abnormalities during growth hormone treatment. J. Pediatr. Gastroenterol. Nutr., 2000, 31, 149-151.
20. Dallman, M. F., Warne, J. P., Foster, M. T. és mtsa: Glucocorticoids and insulin both modulate caloric intake through actions on the brain. J. Physiol., 2007, 583, 431-436.
21. Qi, D., Rodrigues, B.: Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism. Am. J. Physiol. Endocrinol. Metab., 2007, 292, E654-667.
22. Morton, N. M., Seckl, J. R.: 11-beta-hydroxysteroid dehydrogenase type 1 and obesity. Front. Horm. Res., 2008, 36, 146-164.
23. Gross, K. L., Cidlowski, J. A.: Tissue-specifi c glucocorticoid action: A family affair. Trends Endocrinol. Metab., 2008, 19, 331-339.
24. Stimson, R. H., Walker, B. R.: Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Minerva Endocrinol., 2007, 32, 141-159.
25. Gurakuqi, G. C., Stadlbauer, V., Stepan, V. es mtsai: Addison's disease as a rare cause of chronically elevated liver enzymes. Z. Gastroenterol., 2006, 44, 179-183.
26. Rizvi, A. A., Kerrick, J. G.: Liver involvement and abnormal iron variables in undiagnosed Addison's disease. Endocr. Pract., 2001, 7, 184-188.
27. Ersan, O., Demirezer, B.: Addison's disease: A rare cause of hypertransaminasaemia. Dig. Dis. Sci., 2008, 53, 3269-3271.
28. Szafran, H., Smielak-Korombel, W.: The role of estrogens in hormonal regulation of lipid metabolism in women. Przegl. Lek., 1998, 55, 266-270.
29. Shimizu, I., Kohno, N., Tamaki, K. es mtsai: Female hepatology: Favorable role of estrogen in chronic liver disease with hepatitis B virus infection. W. J. Gastroenterol., 2007, 13, 4295-4305.
30. Mattsson, C., Olsson, T.: Estrogens and glucocorticoid hormones in adipose tissue metabolism. 2007, 14, 2918-2924.
31. Louet, J. F., LeMay, C., Mauvais-Jarvis, F.: Antidiabetic actions of estrogen: Insight from human and genetic mouse models. Curr. Atheroscler. Rep., 2004, 6, 180-185.
32. Kapoor, D., Jones, T. H.: Androgen defi ciency as a predictor of metabolic syndrome in aging men: An opportunity for intervention? Drugs Aging, 2008, 25, 357-369.
33. Allan, C. A., Strauss, B. J., Burger, H. G. es mtsai: Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J. Clin. Endocrinol. Metab., 2008, 93, 139-146.
34. Allan, C. A., Strauss, B. J., McLachlan, R. I.: Body composition, metabolic syndrome and testosterone in ageing men. Int. J. Impot. Res., 2007, 19, 448-457.
35. Setji, T. L., Brown, A. J.: Polycystic ovary syndrome: Diagnosis and treatment. Am. J. Med., 2007, 120, 128-132.
36. Carmina, E.: Need for liver evaluation in polycystic ovary syndrome. J. Hepatol., 2007, 47, 313-315.
37. Cerda, C., Perez-Ayuso, R. M., Riquelme, A. es mtsai: Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J. Hepatol., 2007, 47, 313-315.
38. Brzozowska, M. M., Ostapowitz, G., Weltman, M. D.: An association between nonalcoholic fatty liver disease and polycystic ovarian syndrome. J. Gastroenterol. Hepatol., 2009, 24, 243-247.
39. Schenk, S., Saberi, M., Olefsky, J. M.: Insulin sensitivity: Modulation by nutrients and infl ammation. J. Clin. Invest., 2008, 118, 2992-3002.
40. Ahren, B.: GLP-1 and extra-islet effects. Horm. Metab. Res., 2004, 36, 842-845.
41. Moran, T. H., Dailey, M. J.: Minireview: Gut peptides: targets for antiobesity drug development? Endocrinology, 2009, 150, 2526-2530.
42. Potenza, M., Rayfi eld, E. J.: Targeting the incretin system in type 2 diabetes mellitus. Mt. Sinai J. Med., 2009, 76, 244-256.
43. Rabe, K., Lehrke, M., Parhofer, K. G. és mtsa: Adipokines and insulin resistance. Mol. Med., 2008, 14, 741-751.
44. Guzik, T. J., Mangalat, D., Korbut, R.: Adipocytokines. Novel link between infl ammation and vascular function? J. Physiol. Pharmacol., 2006, 57, 505-528.
45. Polyzos, S. A., Kountouras, J., Zavos, C.: Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr. Mol. Med., 2009, 9, 299-314.
46. Havel, P. J.: Update on adipocyte hormones: Regulation of energy balance and carbohydrate/lipid metabolism. Diabetes, 2004, 53, S143-S151.
47. Dyck, D. J.: Adipokines as regulators of muscle metabolism and insulin sensitivity. Appl. Physiol. Nutr. Metab., 2009, 34, 396-402.
48. Maia-Fernandes, T., Roncon-Albuquerque, R. Jr., Leite-Moreira, A. F.: Cardiovascular actions of adiponectin: Pathophysiologic implications. Rev. Port. Cardiol., 2008, 27, 1431-1449.
49. Whitehead, J. P., Richards, A. A., Hickmanm I. J. es mtsai: Adiponectin - a key adipokine in the metabolic syndrome. Diabetes Obes. Metab., 2006, 8, 264-280.
50. Prins, J. B.: Adipose tissue as an endocrine organ. Best. Pract. Res. Clin. Endocrinol. Metabol., 2002, 16, 639-651.